Perritt Capital Management Inc Has $529,000 Stake in Pfizer Inc. (NYSE:PFE)

Perritt Capital Management Inc grew its holdings in Pfizer Inc. (NYSE:PFE) by 2.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,938 shares of the biopharmaceutical company’s stock after acquiring an additional 522 shares during the quarter. Perritt Capital Management Inc’s holdings in Pfizer were worth $529,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the 4th quarter valued at $28,000. Noble Wealth Management PBC acquired a new position in Pfizer in the 4th quarter worth $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the 4th quarter worth about $32,000. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PFE shares. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Citigroup reduced their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

Shares of PFE stock opened at $24.53 on Wednesday. The company has a fifty day moving average price of $26.00 and a two-hundred day moving average price of $26.84. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market cap of $139.09 billion, a P/E ratio of 17.39, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the business posted $0.10 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.